Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| intestinal crypt stem cell | 6 studies | 58% ± 21% | |
| transit amplifying cell | 6 studies | 49% ± 28% | |
| epithelial cell | 5 studies | 38% ± 18% | |
| goblet cell | 4 studies | 26% ± 7% | |
| secretory cell | 3 studies | 36% ± 8% | |
| enterocyte | 3 studies | 22% ± 6% |
Insufficient scRNA-seq data for expression of OLFM4 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| pancreas | 98% | 62859.82 | 321 / 328 | 81% | 1773.10 | 145 / 178 |
| intestine | 62% | 36870.77 | 603 / 966 | 77% | 2343.44 | 407 / 527 |
| prostate | 87% | 13128.37 | 212 / 245 | 44% | 147.74 | 222 / 502 |
| stomach | 35% | 1879.35 | 126 / 359 | 72% | 2387.46 | 207 / 286 |
| kidney | 83% | 3170.02 | 74 / 89 | 1% | 1.34 | 6 / 901 |
| spleen | 77% | 2454.12 | 185 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 74% | 6986.66 | 689 / 929 | 0% | 0 | 0 / 0 |
| lung | 46% | 521.28 | 263 / 578 | 12% | 207.44 | 139 / 1155 |
| bladder | 29% | 2888.24 | 6 / 21 | 28% | 596.11 | 141 / 504 |
| breast | 45% | 715.97 | 206 / 459 | 8% | 72.26 | 94 / 1118 |
| esophagus | 4% | 69.72 | 59 / 1445 | 41% | 979.53 | 75 / 183 |
| uterus | 8% | 97.59 | 13 / 170 | 16% | 126.80 | 74 / 459 |
| liver | 12% | 48.08 | 26 / 226 | 2% | 14.01 | 9 / 406 |
| thymus | 11% | 31.27 | 75 / 653 | 0% | 0.15 | 1 / 605 |
| adipose | 11% | 89.01 | 130 / 1204 | 0% | 0 | 0 / 0 |
| brain | 8% | 27.68 | 210 / 2642 | 0% | 0.08 | 1 / 705 |
| blood vessel | 6% | 29.68 | 86 / 1335 | 0% | 0 | 0 / 0 |
| ovary | 3% | 15.14 | 6 / 180 | 3% | 5.40 | 12 / 430 |
| heart | 5% | 21.83 | 47 / 861 | 0% | 0 | 0 / 0 |
| muscle | 4% | 8.37 | 32 / 803 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 2% | 26.55 | 1 / 45 |
| skin | 2% | 4.73 | 28 / 1809 | 0% | 0.18 | 1 / 472 |
| adrenal gland | 1% | 2.08 | 3 / 258 | 0% | 0.40 | 1 / 230 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0007165 | Biological process | signal transduction |
| GO_0007155 | Biological process | cell adhesion |
| GO_1900026 | Biological process | positive regulation of substrate adhesion-dependent cell spreading |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0035580 | Cellular component | specific granule lumen |
| GO_0048471 | Cellular component | perinuclear region of cytoplasm |
| GO_0005739 | Cellular component | mitochondrion |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0032991 | Cellular component | protein-containing complex |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0042581 | Cellular component | specific granule |
| GO_0045171 | Cellular component | intercellular bridge |
| GO_0042582 | Cellular component | azurophil granule |
| GO_1904724 | Cellular component | tertiary granule lumen |
| GO_0005829 | Cellular component | cytosol |
| GO_0030141 | Cellular component | secretory granule |
| GO_0045296 | Molecular function | cadherin binding |
| GO_0005198 | Molecular function | structural molecule activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | OLFM4 |
| Protein name | Olfactomedin-4 (OLM4) (Antiapoptotic protein GW112) (G-CSF-stimulated clone 1 protein) (hGC-1) (hOLfD) |
| Synonyms | UNQ362/PRO698 GW112 |
| Description | FUNCTION: May promote proliferation of pancreatic cancer cells by favoring the transition from the S to G2/M phase. In myeloid leukemic cell lines, inhibits cell growth and induces cell differentiation and apoptosis. May play a role in the inhibition of EIF4EBP1 phosphorylation/deactivation. Facilitates cell adhesion, most probably through interaction with cell surface lectins and cadherin. . |
| Accessions | ENST00000219022.3 Q6UX06 |
